查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1574931

浸润性乳管癌治疗的市场规模、份额和趋势分析报告：按治疗、类型、分销管道、地区和细分市场预测，2024-2030年

Invasive Ductal Carcinoma Treatment Market Size, Share & Trends Analysis Report By Therapy (Targeted, Hormonal), By Type, By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10个工作天内

价格

浸润性乳管癌治疗市场的成长与趋势：

Grand View Research, Inc.最新报告显示，2024年至2030年，全球浸润性乳管癌治疗市场规模将以8.5%的复合年增长率扩大，预计2030年达到152.1亿美元。

该市场涵盖了有助于管理和护理这种常见乳癌患者的多种因素。

人们对乳癌及其早期发现的认识不断提高，导致更多的女性接受定期筛检。美国癌症协会报告称，定期进行乳房X光摄影检查可以在早期、可治疗的阶段发现乳癌。这种认识的提高有助于早期诊断，随着发现更多病例，对有效 IDC 治疗的需求也在增加。

政府核准流程包括美国食品药物管理局(FDA) 和欧洲药品管理局 (EMA) 等监管机构的严格评估。这些机构在核准之前评估临床试验资料，以确保新治疗方法的安全性和有效性。例如，2024年3月，Astra Zeneca的Truqap（capivasertib）将适用于荷尔蒙受体阳性、HER2阴性、PIK3CA、AKT1或PTEN突变以及内分泌治疗后疾病进展的不可切除或復发性乳癌的成人患者。它已在日本与Faslodex（氟维司群）一起被核准用于患者的治疗。

侵袭性导管癌治疗市场报告亮点

  • 从治疗方法来看，标靶治疗占市场主导地位，2023年销售额份额最大，为64.24%。随着製药公司继续投资开发新型分子标靶药物和联合治疗，分子标靶治疗有望保持其在浸润性乳管癌治疗中的领先地位。
  • 从类型来看，荷尔蒙受体占市场主导地位，2023 年销售额份额最大，为 65.37%。对个人化医疗的认识和重视的提高正在加强荷尔蒙受体治疗市场。随着医疗保健提供者越来越依赖生物标记测试来为个别患者量身定制治疗方案，识别荷尔蒙受体状态对于治疗计划变得至关重要。
  • 从销售管道来看，医院药局占据市场主导地位，2023年销售份额最大，为45.45%。这一优势是由多种因素推动的，包括对在患者接受全面护理的医院环境中进行的化疗和标靶治疗的依赖增加。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章浸润性乳管癌治疗市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 浸润性乳管癌治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章浸润性乳管癌治疗市场：治疗评估与趋势分析

  • 全球浸润性乳管癌治疗市场：治疗仪表板
  • 全球浸润性乳管癌治疗市场：治疗变异分析
  • 全球浸润性乳管癌治疗市场：按收益的治疗
  • 标靶治疗
  • 荷尔蒙疗法
  • 化疗
  • 免疫疗法

第五章浸润性乳管癌治疗市场：类型估计与趋势分析

  • 全球浸润性乳管癌治疗市场：类型仪表板
  • 全球浸润性乳管癌治疗市场：类型变异分析
  • 全球浸润性乳管癌治疗市场：按类型分類的收益
  • 荷尔蒙受体
  • HER2+

第六章浸润性乳管癌治疗市场：通路估计与趋势分析

  • 全球浸润性乳管癌治疗市场：通路仪表板
  • 全球浸润性乳管癌治疗市场：通路波动分析
  • 全球浸润性乳管癌治疗市场：按通路分類的收益
  • 医院药房
  • 零售药房
  • 其他的

第七章浸润性乳管癌治疗市场：按治疗、类型和通路分類的区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第八章 竞争格局

  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 2023年主要企业市场占有率分析
    • Novartis AG
    • Pfizer
    • Merck KGaA
    • Janssen Global Services, LLC
    • F. Hoffmann-La Roche Ltd.
    • AstraZeneca
    • AbbVie Inc.
    • Bristol-Myers Squibb Company
    • Macrogenics, Inc.
    • Celldex Therapeutics
Product Code: GVR-4-68040-444-6

Invasive Ductal Carcinoma Treatment Market Growth & Trends:

The global invasive ductal carcinoma treatment market size is anticipated to reach USD 15.21 billion by 2030, expanding at a CAGR of 8.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market encompasses a wide range of elements that contribute to the management and care of patients diagnosed with this common form of breast cancer.

Increased awareness about breast cancer and its early detection led to more women undergoing regular screenings. The American Cancer Society reports that regular mammograms can detect breast cancer at an earlier stage when it is more treatable. This heightened awareness contributes to earlier diagnosis and increases the demand for effective IDC treatments as more cases are identified.

The government approval process involves rigorous evaluation by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These agencies assess clinical trial data to ensure that new therapies are safe and effective before approval. For instance, in March 2024, AstraZeneca's Truqap (capivasertib) received approval in Japan for use alongside Faslodex (fulvestrant) to treat adult patients with unresectable or recurrent breast cancer that is hormone receptor-positive, HER2-negative, and has alterations in PIK3CA, AKT1, or PTEN after they experienced disease progression following endocrine therapy.

Invasive Ductal Carcinoma Treatment Market Report Highlights:

  • Based on therapy, targeted therapy dominated the market with the largest revenue share of 64.24% in 2023. As pharmaceutical companies continue to invest in developing novel targeted agents and combination therapies, targeted therapy is expected to maintain its leading position in the IDC treatment landscape.
  • Based on type, hormone receptors dominated the market with the largest revenue share of 65.37% in 2023. The growing awareness and emphasis on personalized medicine are enhancing the market for hormone receptor therapies. As healthcare providers increasingly utilize biomarker testing to tailor treatments to individual patients, identifying hormone receptor status has become crucial in treatment planning.
  • Based on distribution channel, hospital pharmacies dominated the market with the largest revenue share of 45.45% in 2023. This dominance is driven by several factors, including the increasing reliance on chemotherapy and targeted therapies administered in hospital settings, where patients receive comprehensive care.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapy
    • 1.2.2. Type
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Therapy Outlook
    • 2.2.2. Type Outlook
    • 2.2.3. Distribution Channel Outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Invasive Ductal Carcinoma Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increased Incidence & Prevalence Rate Of Cancer Worldwide
      • 3.2.1.2. High Investment In R&D
      • 3.2.1.3. Technological Advancement In Cancer Biology & Pharmacology
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Stringent Regulatory Guidelines
      • 3.2.2.2. Expiry Of Patented Drugs
      • 3.2.2.3. Complications Associated With Chemotherapy
  • 3.3. Invasive Ductal Carcinoma Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Invasive Ductal Carcinoma Treatment Market: Therapy Estimates & Trend Analysis

  • 4.1. Global Invasive Ductal Carcinoma Treatment Market: Therapy Dashboard
  • 4.2. Global Invasive Ductal Carcinoma Treatment Market: Therapy Movement Analysis
  • 4.3. Global Invasive Ductal Carcinoma Treatment Market by Treatments, Revenue
  • 4.4. Targeted Therapy
    • 4.4.1. Targeted therapy market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Abemaciclib
      • 4.4.2.1. Abemaciclib market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Ado-Trastuzumab Emtansine
      • 4.4.3.1. Ado-Trastuzumab Emtansine market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Everolimus
      • 4.4.4.1. Everolimus market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Trastuzumab
      • 4.4.5.1. Trastuzumab market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6. Ribociclib
      • 4.4.6.1. Ribociclib market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.7. Palbociclib
      • 4.4.7.1. Palbociclib market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.8. Pertuzumab
      • 4.4.8.1. Pertuzumab market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.9. Olaparib
      • 4.4.9.1. Olaparib market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.10. Others
      • 4.4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Hormonal Therapy
    • 4.5.1. Hormonal therapy market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2. Selective Estrogen Receptor Modulators (SERMs)
      • 4.5.2.1. Selective estrogen receptor modulators (SERMs) market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3. Aromatase Inhibitors
      • 4.5.3.1. Aromatase inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4. Estrogen Receptor Down regulators (ERDs)
      • 4.5.4.1. Estrogen receptor down regulators (ERDs) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Chemotherapy
    • 4.6.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Immunotherapy
    • 4.7.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Invasive Ductal Carcinoma Treatment Market: Type Estimates & Trend Analysis

  • 5.1. Global Invasive Ductal Carcinoma Treatment Market: Type Dashboard
  • 5.2. Global Invasive Ductal Carcinoma Treatment Market: Type Movement Analysis
  • 5.3. Global Invasive Ductal Carcinoma Treatment Market Estimates and Forecasts, By Type, Revenue (USD Million)
  • 5.4. Hormone Receptor
    • 5.4.1. Hormone receptor market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. HER2+
    • 5.5.1. HER2+ market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Invasive Ductal Carcinoma Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Global Invasive Ductal Carcinoma Treatment Market: Distribution Channel Dashboard
  • 6.2. Global Invasive Ductal Carcinoma Treatment Market: Distribution Channel Movement Analysis
  • 6.3. Global Invasive Ductal Carcinoma Treatment Market Estimates and Forecasts, By Distribution Channel, Revenue (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Invasive Ductal Carcinoma Treatment Market: Regional Estimates & Trend Analysis by Therapy, Type, and Distribution Channel

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Vendor Landscape
    • 8.2.1. List of key distributors and channel partners
    • 8.2.2. Key company market share analysis, 2023
    • 8.2.3. Novartis AG
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Pfizer
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Merck KGaA
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Janssen Global Services, LLC
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. F. Hoffmann-La Roche Ltd.
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. AstraZeneca
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. AbbVie Inc.
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Bristol-Myers Squibb Company
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives
    • 8.2.11. Macrogenics, Inc.
      • 8.2.11.1. Company overview
      • 8.2.11.2. Financial performance
      • 8.2.11.3. Product benchmarking
      • 8.2.11.4. Strategic initiatives
    • 8.2.12. Celldex Therapeutics
      • 8.2.12.1. Company overview
      • 8.2.12.2. Financial performance
      • 8.2.12.3. Product benchmarking
      • 8.2.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Invasive ductal carcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 4 North America Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 5 North America Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 U.S. Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 7 U.S. Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 8 U.S. Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Canada Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 10 Canada Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 11 Canada Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 Mexico Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 13 Mexico Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 14 Mexico Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe Invasive ductal carcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 17 Europe Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 18 Europe Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 Germany Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 20 Germany Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 21 Germany Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 UK Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 23 UK Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 24 UK Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 France Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 26 France Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 27 France Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Italy Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 29 Italy Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 30 Italy Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 31 Spain Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 32 Spain Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 33 Spain Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Denmark Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 35 Denmark Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 36 Denmark Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Sweden Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 38 Sweden Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 39 Sweden Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Norway Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 41 Norway Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 42 Norway Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Invasive ductal carcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 China Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 48 China Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 49 China Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Japan Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 51 Japan Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 52 Japan Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 India Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 54 India Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 55 India Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 South Korea Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 57 South Korea Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 Australia Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 60 Australia Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 61 Australia Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Thailand Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 63 Thailand Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 64 Thailand Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 Latin America Invasive ductal carcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 66 Latin America Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 67 Latin America Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 68 Latin America Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69 Brazil Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 70 Brazil Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 71 Brazil Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 72 Argentina Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 73 Argentina Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 74 Argentina Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 MEA Invasive ductal carcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 77 MEA Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 78 MEA Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 South Africa Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 80 South Africa Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 81 South Africa Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 85 UAE Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 86 UAE Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 87 UAE Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modeling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Invasive ductal carcinoma treatment market: market outlook
  • Fig. 7 Invasive ductal carcinoma treatment competitive insights
  • Fig. 8 Parent market outlook
  • Fig. 9 Related/ancillary market outlook
  • Fig. 10 Invasive ductal carcinoma treatment market driver impact
  • Fig. 11 Invasive ductal carcinoma treatment market restraint impact
  • Fig. 12 Invasive ductal carcinoma treatment market: therapy movement analysis
  • Fig. 13 Invasive ductal carcinoma treatment market: therapy outlook and key takeaways
  • Fig. 14 Targeted therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Abemaciclib market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Ado-trastuzumab emtansine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Everolimus market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Trastuzumab market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Ribociclib market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Palbociclib market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Pertuzumab market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Olaparib market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Hormonal therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Selective estrogen receptor modulators (SERMs) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Aromatase inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Estrogen receptor down regulators (ERDs) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Invasive ductal carcinoma treatment market: type movement analysis
  • Fig. 31 Invasive ductal carcinoma treatment market: type outlook and key takeaways
  • Fig. 32 Hormone receptor market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 HER2+ market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Invasive ductal carcinoma treatment market: distribution channel movement analysis
  • Fig. 35 Invasive ductal carcinoma treatment market: distribution channel outlook and key takeaways
  • Fig. 36 Hospital Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Retail Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Global Invasive ductal carcinoma treatment market: Regional movement analysis
  • Fig. 40 Global Invasive ductal carcinoma treatment market: Regional outlook and key takeaways
  • Fig. 41 Global Invasive ductal carcinoma treatment market share and leading players
  • Fig. 42 North America, by country
  • Fig. 43 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. key country dynamics
  • Fig. 45 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Canada key country dynamics
  • Fig. 47 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Mexico key country dynamics
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 UK key country dynamics
  • Fig. 52 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Germany key country dynamics
  • Fig. 54 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 France key country dynamics
  • Fig. 56 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Italy key country dynamics
  • Fig. 58 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Spain key country dynamics
  • Fig. 60 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Denmark key country dynamics
  • Fig. 62 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Sweden key country dynamics
  • Fig. 64 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Norway key country dynamics
  • Fig. 66 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 China key country dynamics
  • Fig. 69 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Japan key country dynamics
  • Fig. 71 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 India key country dynamics
  • Fig. 73 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Thailand key country dynamics
  • Fig. 75 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 South Korea key country dynamics
  • Fig. 77 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Australia key country dynamics
  • Fig. 79 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Brazil key country dynamics
  • Fig. 82 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Argentina key country dynamics
  • Fig. 84 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 South Africa key country dynamics
  • Fig. 87 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Saudi Arabia key country dynamics
  • Fig. 89 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 UAE key country dynamics
  • Fig. 91 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Kuwait key country dynamics
  • Fig. 93 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Market share of key market players- Invasive ductal carcinoma treatment market